耐糖能試験の世界市場

耐糖能試験の世界市場は2030年までに1,198億米ドルに到達

2024年に658億米ドルと推定される耐糖能試験の世界市場は、2024年から2030年にかけてCAGR 10.5%で成長し、2030年には1,198億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるスマートセンサーは、CAGR 11.4%を記録し、分析期間終了時には595億米ドルに達すると予測されます。血糖値検査キットセグメントの成長率は、分析期間中CAGR 11.3％と推定されます。

米国市場は推定179億米ドル、中国はCAGR14.4％で成長予測

米国の耐糖能試験市場は2024年に179億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに248億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.5%と9.3%と予測されています。欧州では、ドイツがCAGR約8.3%で成長すると予測されています。

世界の耐糖能試験市場- 主要動向と促進要因のまとめ

なぜ耐糖能試験は世界的に重要な診断ツールになりつつあるのか？

耐糖能試験（GTT）は、糖代謝に関連する疾患、特に糖尿病や妊娠糖尿病を特定・管理するための最前線の診断薬として大きな注目を集めています。人口の高齢化、座りがちなライフスタイル、食生活の変化などにより、2型糖尿病と耐糖能異常の有病率が上昇し、早期かつ正確な診断プロトコルの需要が劇的に高まっています。これらの検査は、身体がグルコースをいかに効率的に処理するかを評価するためにヘルスケアプロバイダーによって広く採用されており、初期診断と継続的な患者モニタリングの両方に不可欠となっています。

先進経済諸国および新興経済諸国のヘルスケア・システムは、糖尿病負担の増大に対応してスクリーニング・プログラムを拡大しており、それによってGTTをルーチン診断パネルの一部として制度化しています。また、妊娠糖尿病スクリーニングは、妊婦健診における標準的な診療行為となっており、さらに需要に貢献しています。米国糖尿病協会やWHOを含む医学協会によるGTTプロトコルの標準化により、世界の臨床ワークフローにおけるGTTの信頼性と利用がさらに強化されています。この動向は、糖尿病有病率が憂慮すべき速度で上昇し、早期介入戦略が支持を集めているアジア太平洋地域で特に顕著です。

技術革新はGTTの手順と精度をどのように変えているか？

最近の分析化学、診断機器、バイオセンサー技術の進歩により、糖負荷試験の精度、スピード、利便性が大幅に向上しています。従来の経口ブドウ糖負荷試験（OGTT）は、数時間にわたって何度も採血を行う必要があったが、低侵襲で自動化された血液分析システムによって最適化されつつあります。高スループット分析装置、携帯型グルコースモニタリング装置、ポイント・オブ・ケア検査ソリューションは、GTTの実施方法と場所を変え、その範囲を病院の検査室から外来診療所やモバイルヘルス環境へと広げています。

デジタルプラットフォームと電子カルテ（EHR）の統合もまた、検査管理とフォローアップにおいて極めて重要な役割を果たしています。最新のGTTプラットフォームの多くは、リアルタイムのデータ報告、結果の自動解釈、クラウドベースのモニタリングを可能にし、ヘルスケアプロバイダーがより迅速な臨床判断を下せるようになっています。さらに、味付けグルコース溶液や検査ウィンドウの短縮など、患者に優しい検査プロトコルの改善により、患者のコンプライアンスが向上し、検査対象者が拡大しています。これらの技術革新は、十分なサービスを受けていない地域における診断ギャップを埋め、集団規模のスクリーニング・イニシアチブを可能にするのに役立っています。

規制ガイドラインとヘルスケア政策は市場拡大にどのように影響するか？

政策イニシアチブと臨床診療ガイドラインは、糖負荷試験市場の強力な成長触媒となっています。現在、いくつかの国の糖尿病プログラムでは、特に妊婦、メタボリックシンドローム該当者、遺伝的素因を持つ人々を対象に、GTTを用いたハイリスク集団のスクリーニングを義務付けています。公的医療保険制度がある国では、GTTが慢性疾患予防の枠組みの一部として償還されることが増えており、患者にとってはより利用しやすく、診断検査機関にとっては収益性の高いものとなっています。

これと並行して、特にインド、ブラジル、東南アジアのような都市化と生活習慣病が増加している地域では、民間診断チェーンや臨床検査機関の市場参入が増加しています。これらの民間企業は、スケールメリットとデジタルプラットフォームを活用して、費用対効果の高いGTTパッケージを提供しており、多くの場合、他の代謝スクリーニング検査とバンドルされています。さらに、診断企業と抗糖尿病治療薬に携わる製薬企業とのコラボレーションにより、診断と治療のバンドルソリューションがサポートされ、早期診断と治療が連携し、患者の転帰が向上しています。

耐糖能試験市場の成長はいくつかの要因によってもたらされる...

耐糖能試験市場の成長は、代謝異常の発生率の拡大、診断技術の進歩、最終用途の進化と密接に結びついたいくつかの要因によって牽引されています。技術的には、自動分析装置の普及、血液サンプリング装置の改良、GTT投与の信頼性と拡張性を高める統合データ分析プラットフォームが市場の利益をもたらしています。これらの技術革新は診断の分散化を可能にし、GTTをプライマリ・ケアと遠隔地の医療環境の両方で実現可能にしています。

最終用途の面では、予防検診、妊産婦ケア・プロトコル、慢性疾患モニタリング・プログラムへのGTTの統合により、検査基盤が大幅に拡大しています。患者固有のデータが治療経路を決定する個別化医療におけるGTTsの利用拡大も、新たな臨床応用を開拓しています。さらに、在宅検査キット、遠隔医療プラットフォーム、モバイル診断サービスの台頭により、GTTsの利用範囲は従来の臨床環境以外にも広がっています。新興市場では、糖尿病スクリーニングと教育キャンペーンを目的とした官民パートナーシップが、検査の採用をさらに促進しています。これらの要因が相まって、ブドウ糖負荷試験は世界的に強固で進化した状況を形成しています。

セグメント

製品タイプ（スマートセンサー製品タイプ、血糖測定キット製品タイプ、測定器製品タイプ、その他製品タイプ）、疾患適応（反応性低血糖疾患適応、糖尿病低血糖疾患適応、妊娠糖尿病疾患適応、その他疾患適応）、エンドユーザー（病院・診療所エンドユーザー、在宅医療現場エンドユーザー、診断センターエンドユーザー、その他エンドユーザー）

調査対象企業の例（注目の37社）

• Abbott Laboratories
• ACON Laboratories, Inc.
• Ascensia Diabetes Care Holdings AG
• ARUP Laboratories
• Bayer AG
• Cleveland HeartLab, Inc.
• Dexcom, Inc.
• E-Zlab Health Services
• F. Hoffmann-La Roche Ltd
• Healius Limited
• Johnson & Johnson Services, Inc.
• Laboratory Corporation of America Holdings
• LifeScan IP Holdings, LLC
• Medtronic plc
• Merck KGaA
• Nipro Corporation
• Panasonic Corporation
• Penlan Healthcare Ltd.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Glucose Tolerance Tests Market to Reach US$119.8 Billion by 2030

The global market for Glucose Tolerance Tests estimated at US$65.8 Billion in the year 2024, is expected to reach US$119.8 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Smart Sensors, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$59.5 Billion by the end of the analysis period. Growth in the Blood Glucose Testing Kit segment is estimated at 11.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$17.9 Billion While China is Forecast to Grow at 14.4% CAGR

The Glucose Tolerance Tests market in the U.S. is estimated at US$17.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$24.8 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Glucose Tolerance Tests Market - Key Trends & Drivers Summarized

Why Are Glucose Tolerance Tests Becoming a Critical Diagnostic Tool Worldwide?

Glucose tolerance tests (GTTs) have gained significant prominence as frontline diagnostics in identifying and managing disorders related to glucose metabolism, especially diabetes mellitus and gestational diabetes. The rising prevalence of type 2 diabetes and impaired glucose tolerance, driven by aging populations, sedentary lifestyles, and dietary shifts, has dramatically increased the demand for early and accurate diagnostic protocols. These tests are widely employed by healthcare providers to evaluate how effectively the body processes glucose, making them vital for both initial diagnosis and ongoing patient monitoring.

Healthcare systems across developed and emerging economies are expanding their screening programs in response to the growing diabetes burden, thereby institutionalizing GTTs as part of routine diagnostic panels. Gestational diabetes screening has also become a standard practice in antenatal care, further contributing to demand. The standardization of GTT protocols by medical associations, including the American Diabetes Association and WHO, has further reinforced their credibility and usage in clinical workflows globally. This trend is particularly notable in Asia-Pacific, where diabetes prevalence is rising at an alarming rate and early intervention strategies are gaining traction.

How Are Technological Innovations Reshaping GTT Procedures and Accuracy?

Recent advances in analytical chemistry, diagnostic instrumentation, and biosensor technology have significantly enhanced the accuracy, speed, and convenience of glucose tolerance testing. Traditional oral glucose tolerance tests (OGTT), which require multiple blood draws over several hours, are increasingly being optimized with minimally invasive and automated blood analysis systems. High-throughput analyzers, portable glucose monitoring devices, and point-of-care testing solutions are transforming how and where GTTs are conducted, extending their reach from hospital labs to outpatient clinics and mobile health settings.

Integration of digital platforms and electronic health records (EHR) is also playing a pivotal role in test management and follow-up. Many modern GTT platforms are now enabled with real-time data reporting, automatic result interpretation, and cloud-based monitoring, allowing healthcare providers to make faster clinical decisions. Additionally, improvements in patient-friendly test protocols-such as flavored glucose solutions and shorter testing windows-are enhancing patient compliance and expanding the eligible testing population. These innovations are helping bridge the diagnostic gap in underserved regions and enabling population-scale screening initiatives.

How Do Regulatory Guidelines and Healthcare Policies Influence Market Expansion?

Policy initiatives and clinical practice guidelines have become powerful growth catalysts in the glucose tolerance test market. Several national diabetes programs now mandate screening of high-risk populations using GTTs, especially among pregnant women, individuals with metabolic syndrome, and populations with genetic predispositions. In countries with public health insurance systems, GTTs are increasingly being reimbursed as part of chronic disease prevention frameworks, making them more accessible to patients and profitable for diagnostic laboratories.

In parallel, the market is seeing increased participation from private diagnostic chains and clinical laboratories, particularly in regions like India, Brazil, and Southeast Asia, where urbanization and lifestyle diseases are rising. These private players are leveraging economies of scale and digital platforms to offer cost-effective GTT packages, often bundled with other metabolic screenings. Furthermore, collaborations between diagnostic firms and pharmaceutical companies involved in anti-diabetic therapeutics are supporting bundled diagnostic-therapeutic solutions, aligning treatment with early diagnosis and enhancing patient outcomes.

The Growth in the Glucose Tolerance Tests Market Is Driven by Several Factors…

The growth in the glucose tolerance tests market is driven by several factors closely tied to the expanding incidence of metabolic disorders, advancements in diagnostic technologies, and evolving end-use applications. Technologically, the market benefits from the proliferation of automated analyzers, improved blood sampling devices, and integrated data analytics platforms that enhance the reliability and scalability of GTT administration. These innovations are enabling the decentralization of diagnostics, making GTTs feasible in both primary care and remote health settings.

On the end-use side, the integration of GTTs into preventive health checkups, antenatal care protocols, and chronic disease monitoring programs is significantly expanding the testing base. The growing use of GTTs in personalized medicine-where patient-specific data determines treatment pathways-is also opening new clinical applications. Additionally, the rise of home-based testing kits, telemedicine platforms, and mobile diagnostic services is extending the reach of GTTs beyond traditional clinical environments. In emerging markets, public-private partnerships aimed at diabetes screening and education campaigns are further stimulating test adoption. Together, these drivers are shaping a robust and evolving landscape for glucose tolerance testing globally.

SCOPE OF STUDY:

The report analyzes the Glucose Tolerance Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type, Other Product Types); Disease Indication (Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication, Other Disease Indications); End-User (Hospitals & Clinics End-User, Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• ACON Laboratories, Inc.
• Ascensia Diabetes Care Holdings AG
• ARUP Laboratories
• Bayer AG
• Cleveland HeartLab, Inc.
• Dexcom, Inc.
• E-Zlab Health Services
• F. Hoffmann-La Roche Ltd
• Healius Limited
• Johnson & Johnson Services, Inc.
• Laboratory Corporation of America Holdings
• LifeScan IP Holdings, LLC
• Medtronic plc
• Merck KGaA
• Nipro Corporation
• Panasonic Corporation
• Penlan Healthcare Ltd.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Glucose Tolerance Tests - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Diabetes Prevalence Drives Widespread Adoption of Glucose Tolerance Testing
  • Growing Emphasis on Early Detection of Pre-Diabetes Expands Addressable Market for Screening Tests
  • Increased Public Health Spending in Emerging Economies Spurs Diagnostic Infrastructure Development
  • Integration of Glucose Tolerance Tests in Routine Health Checkups Enhances Market Penetration
  • Expansion of Preventive Healthcare Policies Strengthens Business Case for Mass Screening Programs
  • Technological Advancements in Diagnostic Analyzers Propel Accuracy and Adoption of Lab-Based Tests
  • Development of Portable and Point-of-Care Devices Accelerates Demand in Decentralized Settings
  • Adoption of Digital Health Platforms and Home-Based Testing Models Drives Market Transformation
  • Rising Geriatric Population and Associated Risk Factors Generate Sustained Demand for Testing Services
  • Growing Use of Glucose Tolerance Tests in Gestational Diabetes Screening Boosts Testing Volumes
  • Increasing Awareness Campaigns by NGOs and Health Authorities Amplify Demand for Diabetes Testing
  • Integration of AI and Data Analytics in Test Interpretation Enhances Diagnostic Value Proposition
  • Health Insurance Coverage Expansion in Developed Markets Spurs Utilization of Glucose Tolerance Tests
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Glucose Tolerance Tests Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Glucose Tolerance Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Glucose Tolerance Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Smart Sensors Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Smart Sensors Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Smart Sensors Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Blood Glucose Testing Kit Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Blood Glucose Testing Kit Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Blood Glucose Testing Kit Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Meters Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Meters Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Meters Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Homecare Settings End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Diagnostic Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Reactive Hypoglycemia Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Reactive Hypoglycemia Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Reactive Hypoglycemia Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Hypoglycemia Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Diabetes Hypoglycemia Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Diabetes Hypoglycemia Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Gestational Diabetes Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Gestational Diabetes Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Gestational Diabetes Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• CHINA
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Glucose Tolerance Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Glucose Tolerance Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Glucose Tolerance Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• INDIA
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Glucose Tolerance Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Glucose Tolerance Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Glucose Tolerance Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Glucose Tolerance Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Glucose Tolerance Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Glucose Tolerance Tests by Product Type - Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Glucose Tolerance Tests by Product Type - Percentage Breakdown of Value Sales for Smart Sensors Product Type, Blood Glucose Testing Kit Product Type, Meters Product Type and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Glucose Tolerance Tests by End-user - Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Glucose Tolerance Tests by End-user - Percentage Breakdown of Value Sales for Homecare Settings End-User, Diagnostic Centers End-User, Other End-Users and Hospitals & Clinics End-User for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Glucose Tolerance Tests by Disease Indication - Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Glucose Tolerance Tests by Disease Indication - Percentage Breakdown of Value Sales for Reactive Hypoglycemia Disease Indication, Diabetes Hypoglycemia Disease Indication, Gestational Diabetes Disease Indication and Other Disease Indications for the Years 2015, 2025 & 2030

IV. COMPETITION